Endothelial GDF15 deficiency enhances barrier function and mitigates pulmonary fibrosis

Read full text
Authors: Kristen E. Raffensperger, Marta Bueno, Brian J. Philips, Megan Miller, Máté Katona, Shuai Sammy Yuan, Adriana Estrada‐Bernal, Byron Chuan, Pavan Suresh, Stephanie Taiclet, Scott Hahn, Yingze Zhang
+5 more Jonathan K. Alder, Seyed Mehdi Nouraie, Daniel J. Kass, Oliver Eickelberg, Adam C. Straub
Cited by: 1
References: 64

Abstract

Pulmonary fibrosis is frequently accompanied by pulmonary hypertension, which can occur disproportionate to the extent of fibrosis, suggesting a fibrosis-independent vascular remodeling process. Here, we demonstrated that plasma growth differentiation factor 15 (GDF15) is elevated across diverse fibrotic lung disease subtypes and correlates with markers of elevated right heart pressures but not pulmonary function indices, indicating a possible link to endothelial cell dysfunction. To investigate the import of endothelial GDF15 as a modifier of lung fibrosis pathogenesis, we generated endothelial cell-specific Gdf15-KO mice, which showed protection from bleomycin-induced lung injury and fibrosis, with preserved lung function. RNA-seq of human pulmonary microvascular endothelial cells revealed altered expression of barrier-regulatory genes in GDF15-deficient endothelial cells compared with controls. Functional studies confirmed that GDF15 knockdown attenuates thrombin-induced barrier disruption by reducing cytosolic Ca2+ responses. Together, these findings implicate endothelial GDF15 as a modifier of vascular permeability and Ca2+ signaling and a contributor to lung injury and fibrosis.

Fields of Study & Subjects

GDF15 and Related Biomarkers Connective Tissue Growth Factor Research IL-33 ST2 and ILC Pathways

Publication details

Journal / source
JCI Insight
Publisher
American Society for Clinical Investigation
Volume
11
Issue
13
Publication date
23 April 2026
Language
EN